Adagio Medical Holdings, Inc. — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Adagio Medical's board has launched a formal strategic alternatives process to maximize shareholder value, including potential acquisition, merger, or business combination. Concurrently, the company is reducing workforce to align costs with prioritized programs. As of June 30, 2026, Adagio held approximately $7.7M in cash and equivalents—nearly equal to its entire $7.0M market capitalization—while awaiting FDA review of its PMA application for the vCLAS Ventricular Ablation System.
Why this rating
Strategic review + workforce reduction signals distress for micro-cap pre-revenue medical device company. Cash runway ($7.7M) comparable to market cap indicates existential pressure and likely dilutive restructuring ahead.
Tradability signal
NO TRADE
No trade: price $0.34 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.51 ▲ 5.03% | at our read · unknown $0.49 | +10 min · unknown $0.35 ▼ 27.91% | +30 min · unknown $0.30 ▼ 38.17% | +1 hr pending | +4 hrs pending |
The stock had already moved -4.79% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.